Trial reportHuman immunology2010
Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma.
Trial report in Human immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Hypovitaminosis D, oral potentially malignant disorders, and oral squamous cell carcinoma: a systematic review.Medicina oral, patologia oral y cirugia bucal · 2022Pooled it
- Vitamin D in Head and Neck Cancer: a Systematic Review.Current oncology reports · 2020Pooled it
- Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- CAR T Cell Therapy in Lung Cancer: Overcoming Tumor Microenvironment-Mediated Barriers.International journal of biological sciences · 2026Review
- Myeloid-Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations.MedComm · 2025Review
- Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy.Molecular cancer · 2025Review
- Hypovitaminosis D in patients with oral leukoplakia: insights from a cross-sectional study.Frontiers in oncology · 2025Article
- The Magic Triangle in Oral Potentially Malignant Disorders: Vitamin D, Vitamin D Receptor, and Malignancy.International journal of molecular sciences · 2023Review
- Role of Vitamin D in Head and Neck Cancer-Immune Function, Anti-Tumour Effect, and Its Impact on Patient Prognosis.Nutrients · 2023Review
- Role of myeloid-derived suppressor cells in tumor recurrence.Cancer metastasis reviews · 2023Review
- Consideration of possible effects of vitamin D on established cancer, with reference to malignant melanoma.Pigment cell & melanoma research · 2022Review
- Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.Cells · 2021Review
- Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.Signal transduction and targeted therapy · 2021Review
- Complementary Medicine in the Treatment of Cancer Patients.Deutsches Arzteblatt international · 2021Article
- The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review.Journal of clinical and translational research · 2021Review
- Role of myeloid-derived suppressor cells in metastasis.Cancer metastasis reviews · 2021Review
- The role of vitamin D in head and neck cancer.Laryngoscope investigative otolaryngology · 2020Review
- Antitumor effects of targeting myeloid-derived suppressive cells.Translational cancer research · 2020Review
- Impact of dietary vitamin D on initiation and progression of oral cancer.The Journal of steroid biochemistry and molecular biology · 2020Article
- 1α, 25 Dihydroxyvitamin D (1,25(OH)The Journal of steroid biochemistry and molecular biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Prior studies have shown that treatment of head and neck squamous cell carcinoma (HNSCC) patients with 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] reduced intratumoral levels of immune inhibitory CD34(+) progenitor cells while increasing levels of mature progeny dendritic cells. This finding was extended to a pilot study to determine whether 1,25(OH)(2)D(3) treatment concurrently increases levels of intratumoral CD4(+) and CD8(+) T cells, increases intratumoral levels of immune cells expressing the early activation marker CD69, and prolongs time to HNSCC recurrence. The clinical trial comprised 16 patients with newly diagnosed HNSCC being untreated and 16 patients being treated with 1,25(OH)(2)D(3) during the 3-week interval between cancer diagnosis and surgical treatment. Immunologic effects of treatment were monitored by immunohistochemical analyses of surgically removed HNSCC. Clinical effectiveness of 1,25(OH)(2)D(3) treatment in this study was measured by the time to HNSCC recurrence. HNSCC tissues of patients who received treatment with 1,25(OH)(2)D(3) contained increased levels of CD4(+) cells and, more significantly, CD8(+) T cells. Also prominent was an increase in cells expressing the lymphoid activation marker CD69. Results of this pilot study suggest that patients treated with 1,25(OH)(2)D(3) had a lengthier time to tumor recurrence compared with patients who were not treated before surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.